CA2346257C - Procede d'obtention de ngf-.beta. actif - Google Patents

Procede d'obtention de ngf-.beta. actif Download PDF

Info

Publication number
CA2346257C
CA2346257C CA002346257A CA2346257A CA2346257C CA 2346257 C CA2346257 C CA 2346257C CA 002346257 A CA002346257 A CA 002346257A CA 2346257 A CA2346257 A CA 2346257A CA 2346257 C CA2346257 C CA 2346257C
Authority
CA
Canada
Prior art keywords
prongf
ngf
denaturing
beta
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002346257A
Other languages
English (en)
Other versions
CA2346257A1 (fr
Inventor
Rainer Rudolph
Anke Rattenholl
Elisabeth Schwarz
Adelbert Grossmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wacker Chemie AG
Original Assignee
Scil Proteins GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scil Proteins GmbH filed Critical Scil Proteins GmbH
Publication of CA2346257A1 publication Critical patent/CA2346257A1/fr
Application granted granted Critical
Publication of CA2346257C publication Critical patent/CA2346257C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un procédé de préparation de NGF- beta biologiquement actif, à partir de la proforme proNGF. Après expression de la proforme du NGF- beta dans une cellule hôte procaryote, la protéine de recombinée est isolée sous forme d'ensembles inactifs insolubles (corps d'inclusion). Après leur solubilisation dans un agent de dénaturation puissant puis leur conversion à la conformation naturelle qui est déterminée par les ponts disulfure présents dans le NGF- beta naturel, le NGF- beta biologiquement actif est obtenu par séparation de la proséquence.
CA002346257A 1998-10-09 1999-10-11 Procede d'obtention de ngf-.beta. actif Expired - Lifetime CA2346257C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98119077A EP0994188B1 (fr) 1998-10-09 1998-10-09 Procédé d'obtention du NGF-bêta biologiquement actif
EP98119077.0 1998-10-09
PCT/EP1999/007613 WO2000022119A1 (fr) 1998-10-09 1999-10-11 PROCEDE D'OBTENTION DE NGF-β ACTIF

Publications (2)

Publication Number Publication Date
CA2346257A1 CA2346257A1 (fr) 2000-04-20
CA2346257C true CA2346257C (fr) 2005-03-01

Family

ID=8232766

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002346257A Expired - Lifetime CA2346257C (fr) 1998-10-09 1999-10-11 Procede d'obtention de ngf-.beta. actif

Country Status (14)

Country Link
US (2) US8318671B1 (fr)
EP (1) EP0994188B1 (fr)
JP (2) JP4634611B2 (fr)
KR (1) KR100593831B1 (fr)
AT (1) ATE257514T1 (fr)
AU (1) AU765810B2 (fr)
BR (1) BR9914393B1 (fr)
CA (1) CA2346257C (fr)
DE (1) DE59810555D1 (fr)
ES (1) ES2213861T3 (fr)
FR (1) FR17C0007I2 (fr)
NL (1) NL300894I2 (fr)
WO (1) WO2000022119A1 (fr)
ZA (1) ZA200102780B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59810555D1 (de) 1998-10-09 2004-02-12 Scil Proteins Gmbh Verfahren zur Gewinnung von aktivem Beta-NGF
EP1589988A2 (fr) 2002-12-20 2005-11-02 Neuronicon ApS Modulation de l'activite de neurotrophines
EP3225251B1 (fr) 2006-12-21 2020-02-12 H. Lundbeck A/S Modulation de l'activité des proneurotrophines
JP6039146B2 (ja) 2011-12-19 2016-12-07 ワッカー ケミー アクチエンゲゼルシャフトＷａｃｋｅｒ Ｃｈｅｍｉｅ ＡＧ 新規なｐｒｏＮＧＦ変異体およびβ−ＮＧＦ製造におけるその使用
CN103880943A (zh) * 2014-01-20 2014-06-25 厦门北大之路生物工程有限公司 一种rhNGF成熟肽的制备方法
CN106519024A (zh) * 2015-09-15 2017-03-22 三生国健药业（上海）股份有限公司 一种用于去除单克隆抗体中异构体的复性液及复性方法
EP3406259A1 (fr) 2017-05-24 2018-11-28 Dompé farmaceutici S.p.A. Neurotrophines destinées à être utilisées dans le traitement de la perte auditive
CN108467428A (zh) * 2018-03-26 2018-08-31 江苏中新医药有限公司 一种清除rhNGF中N端截短及异常变异体的方法
WO2019207106A1 (fr) 2018-04-27 2019-10-31 Chiesi Farmaceutici Spa Production du facteur de croissance nerveuse (ngf) et de mutéines de celui-ci
MX2021002983A (es) 2018-09-17 2021-05-14 Chiesi Farm Spa Agente para tratamiento de trastornos dermatologicos.
CN110093394B (zh) * 2019-05-10 2023-10-03 重庆科润生物医药研发有限公司 一种蛋白包涵体及重组人β-神经生长因子的制备方法
EP4031117B1 (fr) 2019-09-17 2024-07-24 Chiesi Farmaceutici S.p.A. Mutant de ngf pour utilisation dans le traitement ou la prévention de maladies ophtalmiques
IL302317A (en) 2020-10-28 2023-06-01 Dompe Farm Spa Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them
EP4039269A1 (fr) 2021-02-05 2022-08-10 Dompe' Farmaceutici S.P.A. Isoforme ngf à utiliser dans le traitement des pathologies oculaires
CN117440821A (zh) 2021-04-13 2024-01-23 东佩制药股份公司 用ngf治疗神经性角膜疼痛
EP4311554A1 (fr) 2022-07-29 2024-01-31 Dompé farmaceutici S.p.a. Combinaison pour utilisation en ophtalmologie
EP4316505A1 (fr) 2022-08-05 2024-02-07 Dompé farmaceutici S.p.a. Administration intranasale de ngf pour le traitement de la perte auditive neurosensorielle
EP4342485A1 (fr) 2022-09-23 2024-03-27 Dompe' Farmaceutici S.P.A. Ngf pour le traitement de la spasticité

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169762A (en) * 1983-03-03 1992-12-08 Genentech, Inc. Human nerve growth factor by recombinant technology
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US5683894A (en) 1988-04-29 1997-11-04 University Of California Recombinant nerve growth factor
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
US5606031A (en) 1990-04-06 1997-02-25 Lile; Jack Production and purification of biologically active recombinant neurotrophic protein in bacteria
DE4139000A1 (de) * 1991-11-27 1993-06-03 Boehringer Mannheim Gmbh Verfahren zur gentechnologischen herstellung von biologisch aktivem ss-ngf
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
AU3564595A (en) * 1994-09-12 1996-03-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Biologically active molecules derived from neurotrophins
US5935824A (en) * 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
AU714318B2 (en) 1996-06-11 2000-01-06 Roche Diagnostics Gmbh Process for the activation of denatured protein
DE59810555D1 (de) 1998-10-09 2004-02-12 Scil Proteins Gmbh Verfahren zur Gewinnung von aktivem Beta-NGF

Also Published As

Publication number Publication date
ATE257514T1 (de) 2004-01-15
AU765810B2 (en) 2003-10-02
US8318671B1 (en) 2012-11-27
WO2000022119A1 (fr) 2000-04-20
US8501439B2 (en) 2013-08-06
NL300894I2 (nl) 2018-02-01
KR20010083900A (ko) 2001-09-03
DE59810555D1 (de) 2004-02-12
JP5275306B2 (ja) 2013-08-28
CA2346257A1 (fr) 2000-04-20
JP4634611B2 (ja) 2011-02-16
ZA200102780B (en) 2002-07-04
BR9914393B1 (pt) 2021-06-22
US20100203589A1 (en) 2010-08-12
BR9914393A (pt) 2001-06-26
EP0994188A1 (fr) 2000-04-19
EP0994188B1 (fr) 2004-01-07
FR17C0007I1 (fr) 2017-11-17
FR17C0007I2 (fr) 2018-11-09
KR100593831B1 (ko) 2006-06-28
JP2002527062A (ja) 2002-08-27
ES2213861T3 (es) 2004-09-01
AU1034800A (en) 2000-05-01
JP2010280717A (ja) 2010-12-16

Similar Documents

Publication Publication Date Title
US8501439B2 (en) Method for obtaining active pro-NGF and beta-NGF
JP6622683B2 (ja) 新規なｐｒｏＮＧＦ変異体およびβ−ＮＧＦ製造におけるその使用
Weselake et al. Purification and characteristics of an endogenous α-amylase inhibitor from barley kernels
BRPI9914393B1 (pt) Método para a preparação de pro-ngf biologicamente ativo, bem como uso de pro-ngf recombinante
US5223483A (en) Cysteine-modified acidic fibroblast growth factor
AU714318B2 (en) Process for the activation of denatured protein
US5210028A (en) Process for the production of unfused igf-ii protein in e. coli
EP0319052B1 (fr) Mutéine de facteur de croissance de fibroblaste
EP1506295B1 (fr) Muteines de facteur de croissance placentaire de type 1, leur procede de preparation et leur application
US5312911A (en) Cysteine-modified acidic fibroblast growth factor
JP3932475B2 (ja) 新規フェリチン
JPH1080281A (ja) 新規蛋白質及びその製造方法
WO1994003492A1 (fr) Variantes de l'interleukine-6 et leurs utilisations
KR0132003B1 (ko) 스트렙토마이세스 써모니트리피컨스 아미노펩티다제를 이용한 천연형 재조합 단백질의 제조방법
JP2003189865A (ja) 繊維芽細胞成長因子をコードする組み換えベクター

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20191011